Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study

被引：0

作者：

Shiori Hishida-Sadaka

Hirotoshi Iihara

Koichi Ohata

Serika Matsuoka

Daichi Watanabe

Takuji Iwashita

Shinya Uemura

Masahito Shimizu

Akio Suzuki

机构：

[1] Gifu University Hospital,Department of Pharmacy

[2] Gifu University Hospital,Patient Safety Division

[3] Gifu Pharmaceutical University,Laboratory of Pharmacy Practice and Social Science

[4] Gifu University Graduate School of Medicine,Department of Gastroenterology

[5] Gifu Pharmaceutical University,Laboratory of Advanced Medical Pharmacy

来源：

Supportive Care in Cancer | 2023年 / 31卷

关键词：

Advanced pancreatic cancer; Antiemetic therapy; Chemotherapy; Chemotherapy-induced nausea and vomiting;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

下载

共 45 条

[21] Palonosetron Versus Other 5-HT3 Receptor Antagonists for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer on Chemotherapy in a Hospital Outpatient Setting
Balu, Sanjeev
Buchner, Deborah
Craver, Chris
Gayle, Julie
CLINICAL THERAPEUTICS, 2011, 33 (04) : 443 - 455
[22] A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients
George Dranitsaris
Mehdi Moezi
Kate Dobson
Robert Phelan
Sibel Blau
Supportive Care in Cancer, 2022, 30 : 6649 - 6658
[23] A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients
Dranitsaris, George
Moezi, Mehdi
Dobson, Kate
Phelan, Robert
Blau, Sibel
SUPPORTIVE CARE IN CANCER, 2022, 30 (08) : 6649 - 6658
[24] Aprepitant/5HT-3 antagonist (EMEND) for the prevention of chemoradiation-induced nausea and vomiting (CRINV) in patients receiving gemcitabine/5-FU-based chemoradiation and concurrent upper abdominal radiation for pancreatic cancer
Blackstock, A. W.
Aklilu, M.
Lovato, J.
Degrass, L.
Sommer, J.
Howerton, R.
Mishra, G.
Levine, E.
McQuellon, R.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[25] Randomized phase II trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate with ondansetron (ond)/dexamethasone (dex) for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC).
Rolski, J.
Ramlau, R.
Dediu, M.
Russo, M. W.
Ross, G. A.
Mather, R. A.
Bandekar, R. R.
Grunberg, S. M.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 471S - 471S
[26] Olanzapine combined with 5-HT3 RA plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: A systematic review and meta-analysis of randomized controlled trials
Zhou, J-G.
ANNALS OF ONCOLOGY, 2019, 30
[27] Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies
Aapro, Matti
Navari, Rudolph M.
Roeland, Eric
Zhang, Li
Schwartzberg, Lee
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 157
[28] Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials
Zhou, Jian-Guo
Huang, Lang
Jin, Su-Han
Xu, Cheng
Frey, Benjamin
Ma, Hu
Gaipl, Udo S.
ESMO OPEN, 2020, 5 (01)
[29] Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)
Schwartzberg, L.
Aapro, M. S.
ANNALS OF ONCOLOGY, 2019, 30 : 722 - 722
[30] Pooled analysis of efficacy and safety of palonosetron 0.75 mg IV for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving cisplatin for lung cancer - Palonosetron Japanese Cooperative Study Group for lung cancer
Ogura, Takashi
Segawa, Yoshihiko
Sekine, Ikuo
Masuda, Noriyuki
Katakami, Nobuyuki
Sakai, Hiroshi
Kubota, Kaoru
Imamura, Fumio
Atagi, Shinji
Yoshizawa, Hirohisa
Kitagawa, Chiyoe
Takeda, Yuichiro
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S368 - S369

← 1 2 3 4 5 →